AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective Capabilities
According to the company, the deal is an important strategic step for AstraZeneca, strengthening its portfolio of promising anti-infective treatments from external opportunities and providing a widely recognised expert group and technology platform in an area of research that complements internal capabilities in anti-bacterials. The deal also fits with AstraZeneca's decision to re-focus its disease area research with infection and anti-bacterials now one of the company's key therapy areas.
The anti-viral programmes developed by Arrow Therapeutics, include several different approaches towards Hepatitis C Virus (HCV) and Respiratory Syncytial Virus (RSV). The acquisition of Arrow Therapeutics augments AstraZeneca's portfolio with clinical and pre-clinical compounds and programmes. These assets include two anti-HCV compounds which both target the novel NS5a protein, including A-831 in Phase I. Arrow's most advanced compound is RSV604, currently in Phase II clinical development and partnered with Novartis. RSV604 is a first-in-class, small molecule, oral anti-RSV compound.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.